Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes.
Tian J, Song YP, Zhang GC, Wang SF, Chu XX, Chai Y, Wang CL, He AL, Zhang F, Shen XL, Zhang WH, Yang LH, Nie DN, Wang DM, Zhu HL, Gao D, Lou SF, Zhou ZP, Su GH, Li Y, Lin JY, Shi QZ, Ouyang GF, Jing HM, Chen SJ, Li J, Mi JQ. Tian J, et al. Among authors: song yp. J Cancer Res Clin Oncol. 2024 Apr 11;150(4):189. doi: 10.1007/s00432-024-05700-x. J Cancer Res Clin Oncol. 2024. PMID: 38605258 Free PMC article. Clinical Trial.
Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, Shao ZH, Ren HY, Hu JD, Xu KL, Wang JW, Song YP, Fang MY, Li J, Yan XY, Huang XJ. Zhu HH, et al. Among authors: song yp. Lancet Oncol. 2018 Jul;19(7):871-879. doi: 10.1016/S1470-2045(18)30295-X. Epub 2018 Jun 5. Lancet Oncol. 2018. PMID: 29884593 Clinical Trial.
Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
Xu PP, Fu D, Li JY, Hu JD, Wang X, Zhou JF, Yu H, Zhao X, Huang YH, Jiang L, Liu F, Su LP, Chen ZW, Zeng QS, Chen JP, Fang MY, Ma J, Liu T, Song YP, Yu K, Li Y, Qiu LG, Chen XQ, Gu J, Yan JS, Hou M, Huang HY, Wang L, Cheng S, Shen Y, Xiong H, Chen SJ, Zhao WL. Xu PP, et al. Among authors: song yp. Lancet Haematol. 2019 Jun;6(6):e328-e337. doi: 10.1016/S2352-3026(19)30051-1. Lancet Haematol. 2019. PMID: 31126528 Clinical Trial.
2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy.
Zhang X, Chen F, Chen X, Cheng Y, Fang M, Feng J, Fu H, Gao H, Han Y, He A, Hou M, Hu Y, Huang R, Huang W, Jing Z, Kong P, Liang A, Liang M, Liu D, Liu J, Liu L, Liu X, Ma L, Mei H, Ni H, Niu T, Peng J, Qiao J, Ren J, Song Y, Tang LV, Tong T, Wang S, Wang X, Wang Z, Wei H, Wu D, Wu G, Xu C, Xu X, Xu Y, Yang L, Yang R, Yang T, Yin C, Yu L, Zhang G, Zhang L, Zhang L, Zhang X, Zhao W, Zhao Y, Zhou D, Zhou H, Zhou Z, Zhu T, Wang J, Huang X. Zhang X, et al. Chin Med J (Engl). 2022 Apr 20;135(8):887-889. doi: 10.1097/CM9.0000000000002043. Chin Med J (Engl). 2022. PMID: 35730369 Free PMC article. No abstract available.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2022 Oct 31;15(1):159. doi: 10.1186/s13045-022-01369-2. J Hematol Oncol. 2022. PMID: 36316695 Free PMC article. No abstract available.
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. J Hematol Oncol. 2023 Feb 20;16(1):13. doi: 10.1186/s13045-023-01414-8. J Hematol Oncol. 2023. PMID: 36803531 Free PMC article. Clinical Trial. No abstract available.
Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
Deng LJ, Zhou KS, Liu LH, Zhang MZ, Li ZM, Ji CY, Xu W, Liu T, Xu B, Wang X, Gao SJ, Zhang HL, Hu Y, Li Y, Cheng Y, Yang HY, Cao JN, Zhu ZM, Hu JD, Zhang W, Jing HM, Ding KY, Zhang XY, Zhao RB, Zhang B, Tian YM, Song YP, Song YQ, Zhu J. Deng LJ, et al. Among authors: song yq, song yp. Blood Adv. 2023 Aug 22;7(16):4349-4357. doi: 10.1182/bloodadvances.2022009168. Blood Adv. 2023. PMID: 37078706 Free PMC article. Clinical Trial.
421 results